ImmuPharma (LON:IMM) Trading Up 27.3% - Should You Buy?

Key Points

• ImmuPharma's stock surged 27.3% during mid-day trading, reaching a high of GBX 12.75, after closing at GBX 9.90, despite a 46% decrease in trading volume.
• The company has a market capitalization of £63.34 million and a highly negative price-to-earnings ratio of -1,415.73.
• ImmuPharma specializes in peptide-based therapeutics, focusing on treatments for autoimmune diseases, with its lead product being P140 (Lupuzor™).

ImmuPharma plc (LON:IMM - Get Free Report) was up 27.3% during mid-day trading on Friday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares traded hands during trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Up 27.3%

The firm has a market capitalization of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53. The stock's 50-day moving average price is GBX 7.70 and its 200 day moving average price is GBX 4.29.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.